Instead of asking 'why not stack them,' the question becomes 'what specific outcome justifies adding a second compound with incomplete human safety data?' For research exploring maximal metabolic intervention where single-agent tirzepatide has plateaued, the stack may be defensible
In short-term trials, particularly those involving HIV patients experiencing muscle wasting, the hormone has been administered in doses up to 0.1mg per kg of body weight for up to three months
The latter may be caused by intestinal disorders, infections, bariatric surgery, or pharmacological interference, including histamine H2 receptor antagonists and metformin
Higher NPC1L1 expression in late-stage ovarian tumors is connected to worse survival, suggesting that its inhibition could be beneficial [124]
The literature supports GHK-Cu here strongly: Leyden et al
Potential natural products for the management of autism spectrum disorder